Skip to main content

melanoma Archives

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

Aug. 8, 2023—A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.

Read more


Study identifies key regulator of melanoma development

Jun. 29, 2023—Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.

Read more


Couple’s gift helps support immunotherapy research

Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

Read more


Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Read more


Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Read more


Forty-three percent of melanoma patients have chronic complications from immunotherapies

Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Read more


Study reveals new strategy for reducing tumor growth, metastasis

Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Read more


Study explores melanoma drug’s effectiveness

Apr. 23, 2020—A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

Read more


Potential second-line melanoma treatment identified

Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

Read more


Hot chemotherapy surgery helps save patient’s leg

Mar. 28, 2019—Tom Deweese can keep up with his grandchildren because of a highly specialized surgery using hot chemotherapy that saved his leg.

Read more


Entertainers’ support strengthens VICC melanoma research efforts

Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.

Read more


“Idling” cancer cells may return

Apr. 11, 2018—Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more